2. Signaling Pathways
  3. Immunology/Inflammation
  4. Galectin
  5. Galectin Inhibitor

Galectin Inhibitor

Galectin Isoform Comparison

Galectin Inhibitors (38):

Cat. No. Product Name Effect Purity
  • HY-114409
    GB1107
    		Inhibitor 99.92%
    GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a Kd of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model.
  • HY-19940
    Olitigaltin
    		Inhibitor 99.74%
    TD139 is a synthetic galectin-3 inhibitor. TD139 has high affinity for galectin-3 with a Kd of 68 nM, a Kd of 0.22 μM for galectin-1, and a Kd of 38 μM for galectin-7.
  • HY-19756
    OTX008
    		Inhibitor 99.94%
    OTX008 is a selective inhibitor of galectin-1.
  • HY-130208
    Thiodigalactoside
    		Inhibitor 99.97%
    Thiodigalactoside (TDG) is an orally active and potent galectin (GAL) inhibitor with Kd values of 24 μM, 49 μM for GAL1 and GAL3, respectively. Thiodigalactoside, a non-metabolizable disaccharide, has anti-inflammatory and anti-cancer activity. Thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats.
  • HY-147041
    Selvigaltin
    		Inhibitor 99.89%
    Selvigaltin (GB1211) is an orally active galectin-3 small molecule inhibitor with an IC50 value of 12 nM in rabbits, showing anti-tumor activity. Selvigaltin decreases galectin-3 levels in the liver and reduces biomarkers of liver function (AST, ALT, bilirubin), inflammation (cells foci) and fibrosis (PSR, SHG), as well as decreasing the mRNA and protein expression of several key inflammation and fibrosis biomarkers (IL6, TGFβ3, SNAI2, collagen). Selvigaltin restores T-cell activity and induces less tumors and metastasis.
  • HY-179410
    Galectin-3-IN-7
    		Inhibitor
    Galectin-3-IN-7 is a selective Galectin-3 inhibitor with a Kd of 5.7 nM and shows 390-fold selectivity over Gal-1. Galectin-3-IN-7 can downregulate profibrotic signaling such as ACTA2, COL1A2, and FN1 in TGFβ-stimulated LX2 hepatic stellate cells. Galectin-3-IN-7 can be used for the research of fibrosis.
  • HY-181648
    Gal-1-IN-1
    		Inhibitor
    Gal-1-IN-1 is a potent and selective human galectin-1 (hGal-1) inhibitor with a Ki of 0.022 μM. Gal-1-IN-1 blocks hGal-1 binding to tumor cells and suppresses human galectin-1-induced pre-apoptosis state. Gal-1-IN-1 reduces hGal-1-expressing cancer cell viability. Gal-1-IN-1 can be used for the research of breast cancer.
  • HY-128852
    N-Acetyl-D-galactosamine, 98%
    		Inhibitor 99.85%
    N-Acetyl-D-galactosamine (GalNAc) is a terminal essential amino sugar derived from galactose and forms the antigens of blood group A in humans. N-Acetyl-D-galactosamine (GalNAc) interact with Soya bean agglutinin (SBA), hence decreasing the effects of SBA on cellular membrane permeability and tight junction protein expression in piglets. N-Acetyl-D-galactosamine (GalNAc) inhibits the hemagglutinating activity by the lectin.
  • HY-114440
    Belapectin
    		Inhibitor 98.94%
    Belapectin (GR-MD-02) is a Galectin-3 (Gal-3) inhibitor. Belapectin drives tumor-induced immunosuppression by inducing T cell Apoptosis. Belapectin promotes tumor regression and improves survival of tumor-bearing mice through a CD8+ T cell-dependent mechanism. Belapectin binds to Gal-3 with affinity Ki of 2.8 μM.
  • HY-126854
    N-Acetyllactosamine
    		Inhibitor 99.95%
    N-Acetyllactosamine (N-Acetyl-D-lactosamine), a nitrogen-containing disaccharide, is a galectin-3 inhibitor, which is an important component of various oligosaccharides such as glycoproteins and sialyl Lewis X. N-Acetyllactosamine can be used as the starting material for the synthesis of various oligosaccharides. N-Acetyllactosamine has prebiotic effects.
  • HY-W150340
    β-Lactose
    		Inhibitor 99.31%
    β-Lactose is a disaccharide commonly found in milk and dairy products. It consists of two monosaccharides, glucose and galactose, linked by β-glycosidic bonds. β-Lactose has various applications in the food industry, especially as a sweetener and bulking agent. Furthermore, it can be used as a substrate for enzymes involved in lactose metabolism and as a model compound for studying carbohydrate-protein interactions.
  • HY-P990242
    Anti-Mouse Galectin-9 Antibody (RG9-1)
    		Inhibitor
    Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4+ and CD8+ T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia.
  • HY-P991228
    LYT-200
    		Inhibitor 99.16%
    LYT-200 is a humanized monoclonal antibody against galectin-9 (Galectin-9). LYT-200 binds to galectin-9 expressed on the surface of hematologic malignant cells, inhibits pro-leukemic functions and induces cell death. LYT-200 can be used in research related to hematologic malignancies.
  • HY-162561
    GB1908
    		Inhibitor 98.94%
    GB1908 is a selective and orally active galectin-1 inhibitor with Ki values of 57 nM and 72 nM for human and mouse galectin-1, respectively. GB1908 displays >50-fold selectivity over galectin-3. GB1908 can be used for the study of lung cancer.
  • HY-P990198
    Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166)
    		Inhibitor
    Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is a rat-derived anti-mouse/human Mac-2/Galectin-3 IgG2a monoclonal antibody. Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) significantly inhibits IL-6 expression (inhibition rates 34.7% and 55.3%). Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is often used for immunoprecipitation, western blot, immunofluorescence, and flow cytometry.
  • HY-150235
    Galectin-8N-IN-1
    		Inhibitor 98.09%
    Galectin-8N-IN-1 (compound 19a) is a potent and selective galectin-8N inhibitor with a Kd value of 1.8 μM. Galectin-8N-IN-1 is a galectin-8N ligand. Galectin-8N-IN-1 can be used in research of immune system.
  • HY-155191
    Galectin-3/galectin-8-IN-1
    		Inhibitor 99.53%
    Galectin-3/galectin-8-IN-1 (Compound 53) is a dual Galectin-3 and galectin-8 C-terminal domain inhibitor, with Kd values of 4.12 μM and 6.04 μM respectively. Galectin-3/galectin-8-IN-1 inhibits the MRC-5 lung fibroblast cells migration. Galectin-3/galectin-8-IN-1 can be used for research of cancer and tissue fibrosis.
  • HY-170510
    GB2095
    		Inhibitor 98.92%
    GB2095 is an orally active and selective galectin-3 inhibitor. GB2095 shows superior selectivity for both human (KD = 0.036 μM) and mouse galectin-3 (KD = 0.35 μM) over other galectins (such as h-Gal-1/4N/4C/8N/8C/9N/9C and m-galectin-1). GB2095 inhibits tumor growth in syngeneic mouse models of breast and melanoma cancers. GB2095 can be used for breast and melanoma cancer research.
  • HY-144312
    Thiobis-β-Galactose-propyne
    		Inhibitor 99.76%
    Thiobis-β-Galactose-propyne is an effective multivalent galectin-3 (Gal-3) inhibitor. Galectin-3 is involved in many metabolism processes related to cancer. Galectin-3-IN-1 is a click chemistry reagent. It contains an alkyne group that can undergo a copper-catalyzed azide-alkyne cycloaddition (CuAAc) reaction with molecules that have an azide group.
  • HY-P10010
    DB21, Galectin-1 Antagonist
    		Inhibitor
    DB21, Galectin-1 Antagonist is a dibenzofuran conjugated peptidomimetic that acts as an allosteric inhibitor of galectin-1 (GAL1)binding to cell surface glycans. DB21, Galectin-1 Antagonis increases inhibition of angiogenesis and tumour growth in melanoma, lung adenocarcinoma and ovarian cancer models.